University of Texas/MD Anderson Cancer Center MD Anderson PSC — Houston, Texas

University of Texas/MD Anderson Cancer Center MD Anderson PSC is a clinical research site located in Houston, Texas, United States 77030-4009.

Crixeo Health Trust Score: 65/100 (FAIR). This profile has not yet been claimed by the site owner.

University of Texas/MD Anderson Cancer Center MD Anderson PSC has participated in 3 clinical trials.

Therapeutic areas: Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor, Advanced/Metastatic Solid Tumors or Lymphomas.

Sponsors: Pfizer, Chinook Therapeutics, Inc. (formerly Aduro), Array Biopharma, now a wholly owned subsidiary of Pfizer.

Sponsor Feasibility Report

Trust Score: 65/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Texas/MD Anderson Cancer Center MD Anderson PSC?

University of Texas/MD Anderson Cancer Center MD Anderson PSC has a Crixeo Trust Score of 65/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Texas/MD Anderson Cancer Center MD Anderson PSC conducted?

University of Texas/MD Anderson Cancer Center MD Anderson PSC has 3 clinical trials on record. Their work covers Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor, Advanced/Metastatic Solid Tumors or Lymphomas.

Is University of Texas/MD Anderson Cancer Center MD Anderson PSC accredited by Crixeo Health?

University of Texas/MD Anderson Cancer Center MD Anderson PSC has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Texas/MD Anderson Cancer Center MD Anderson PSC?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.